These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 28607601)

  • 1. Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.
    Berry JS; Vreeland TJ; Hale DF; Jackson DO; Trappey AF; Greene JM; Hardin MO; Herbert GS; Clifton GT; Peoples GE
    J Cancer; 2017; 8(7):1255-1262. PubMed ID: 28607601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase Ib trial of folate binding protein (FBP)-derived peptide vaccines, E39 and an attenuated version, E39': An analysis of safety and immune response.
    Vreeland TJ; Litton JK; Qiao N; Philips AV; Alatrash G; Hale DF; Jackson DO; Peace KM; Greene JM; Berry JS; Clifton GT; Peoples GE; Mittendorf EA
    Clin Immunol; 2018 Jul; 192():6-13. PubMed ID: 29574039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.
    Brown TA; Byrd K; Vreeland TJ; Clifton GT; Jackson DO; Hale DF; Herbert GS; Myers JW; Greene JM; Berry JS; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwel GL; Peoples GE
    Cancer Med; 2019 Aug; 8(10):4678-4687. PubMed ID: 31274231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients.
    Kim DK; Lee TV; Castilleja A; Anderson BW; Peoples GE; Kudelka AP; Murray JL; Sittisomwong T; Wharton JT; Kim JW; Ioannides CG
    Anticancer Res; 1999; 19(4B):2907-16. PubMed ID: 10652572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparison of cytotoxic T-lymphocyte effects of dendritic cells stimulated by the folate binding protein peptide cultured with IL-15 and IL-2 in solid tumor.
    Kim DK; Kim JH; Kim YT; Kim JW; Ioannides CG
    Yonsei Med J; 2002 Dec; 43(6):691-700. PubMed ID: 12497651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
    Jackson DO; Byrd K; Vreeland TJ; Hale DF; Herbert GS; Greene JM; Schneble EJ; Berry JS; Trappey AF; Clifton GT; Hardin MO; Martin J; Elkas JC; Conrads TP; Darcy KM; Hamilton CA; Maxwell GL; Peoples GE
    Oncotarget; 2017 Feb; 8(9):15912-15923. PubMed ID: 27852036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers.
    Peoples GE; Anderson BW; Lee TV; Murray JL; Kudelka AP; Wharton JT; Ioannides CG
    Clin Cancer Res; 1999 Dec; 5(12):4214-23. PubMed ID: 10632363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53.
    Chhabra A; Mukherji B; Batra D
    Expert Opin Ther Targets; 2017 Feb; 21(2):117-129. PubMed ID: 27935327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro.
    Van Waes C; Monach PA; Urban JL; Wortzel RD; Schreiber H
    Tissue Antigens; 1996 May; 47(5):399-407. PubMed ID: 8795140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
    Cormier JN; Salgaller ML; Prevette T; Barracchini KC; Rivoltini L; Restifo NP; Rosenberg SA; Marincola FM
    Cancer J Sci Am; 1997; 3(1):37-44. PubMed ID: 9072306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
    Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
    BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
    Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
    Rice J; Elliott T; Buchan S; Stevenson FK
    J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
    Bristol JA; Schlom J; Abrams SI
    J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of c-Jun N-terminal kinase rescues influenza epitope-specific human cytolytic T lymphocytes from activation-induced cell death.
    Mehrotra S; Chhabra A; Hegde U; Chakraborty NG; Mukherji B
    J Leukoc Biol; 2007 Feb; 81(2):539-47. PubMed ID: 17062604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine Trials for the Clinician: Prospects for Tumor Antigens.
    Osanto S
    Oncologist; 1997; 2(5):284-299. PubMed ID: 10388061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E; Celis E
    J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
    Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
    J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation-induced cell death of human melanoma specific cytotoxic T lymphocytes is mediated by apoptosis-inducing factor.
    Chhabra A; Mehrotra S; Chakraborty NG; Dorsky DI; Mukherji B
    Eur J Immunol; 2006 Dec; 36(12):3167-74. PubMed ID: 17109472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes.
    Melief CJ; Van Der Burg SH; Toes RE; Ossendorp F; Offringa R
    Immunol Rev; 2002 Oct; 188():177-82. PubMed ID: 12445291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.